Sales and Marketing

The former head of the Biomedical Advanced Research and Development Authority (BARDA) has warned that due to the US’s handling …

Michael Varney, industry veteran and Head of Research & Development at Genentech, has announced he is to leave the role …

The news this week continues to be dominated by COVID-19 vaccines and treatments, with the NIAID announcing the launch of …

Remdesivir, perhaps the leading hope in the race against COVID-19, has secured approval from Japan’s Ministry of Health, Labour and …

Dr LaRee Tracy, a lecturer at San Diego State University and Director of Biostatistics at PHASTAR, led a team of …

The European Commission has awarded marketing approval to Takeda’s subcutaneous formulation of its gut-selective biologic therapy Entyvio (vedolizumab) as a …

The results of another study into the use of hydroxychloroquine in COVID-19 patients has cast further doubts on its effectiveness …

Lynparza (olaparib), developed by AstraZeneca and MSD, has secured FDA approval when paired with bevacizumab as a first-line maintenance treatment …

The FDA has announced that Retevmo (selpercatinib) has been approved to treat both non-small-cell lung cancer (NSCLC) and medullary thyroid …

The US National Institute of Allergy and Infectious Diseases (NAID) has announced that it is enrolling COVID-19 patients in hospital …

NICE has revealed that it has recommended the NHS use of Roche’s Kadcyla (trastuzumab emtansine) for HER2+ breast cancer in …

The FDA has awarded marketing authorisation to Novartis for the Oral MET inhibitor Tabrecta (capmatinib) for the first-line treatment of metastatic non-small …

The FDA has moved to approve an oral tablet formulation of AstraZeneca’s Farxiga (dapagliflozin) to reduce the risk of cardiovascular …

Alexion has announced it is to acquire Boston-based blood disorder specialist Portola Pharmaceuticals in a transaction to the value of …

“Every professional faces challenges. As a woman in industry, particularly in leadership, it adds another dimension to those challenges in …